BrightSpring Health Services Announces Onco360® Has Been Selected as a Partner for Several New Drugs
BrightSpring Health Services (NASDAQ: BTSG) announces that its specialty pharmacy partner, Onco360®, has been selected as the national pharmacy partner for multiple new medications treating advanced cancers and blood diseases. Eight new medications have been added to Onco360's distribution network, including treatments for: breast cancer (ITOVEBI™), myelodysplastic syndromes (Rytelo™), brain tumors (Voranigo®), paroxysmal nocturnal hemoglobinuria (PIASKY®), esophageal cell carcinoma (Tevimbra®), non-small cell lung cancer (LAZCLUZE™), acute leukemias (Revuforj®), and gastric tumors (Vyloy®).
BrightSpring Health Services (NASDAQ: BTSG) annuncia che il suo partner di farmacia specializzato, Onco360®, è stato selezionato come partner farmaceutico nazionale per diversi nuovi farmaci che trattano cancro avanzato e malattie del sangue. Otto nuovi farmaci sono stati aggiunti alla rete di distribuzione di Onco360, inclusi trattamenti per: cancro al seno (ITOVEBI™), sindromi mielodisplastiche (Rytelo™), tumori cerebrali (Voranigo®), emoglobinuria parossistica notturna (PIASKY®), carcinoma a cellule esofagee (Tevimbra®), cancro polmonare non a piccole cellule (LAZCLUZE™), leucemie acute (Revuforj®) e tumori gastrici (Vyloy®).
BrightSpring Health Services (NASDAQ: BTSG) anuncia que su socio de farmacia especializada, Onco360®, ha sido seleccionado como el socio farmacéutico nacional para múltiples nuevos medicamentos que tratan cánceres avanzados y enfermedades de la sangre. Se han añadido ocho nuevos medicamentos a la red de distribución de Onco360, incluidos tratamientos para: cáncer de mama (ITOVEBI™), sindromes mielodisplásicos (Rytelo™), tumores cerebrales (Voranigo®), hemoglobinuria paroxística nocturna (PIASKY®), carcinoma de células esofágicas (Tevimbra®), cáncer de pulmón no microcítico (LAZCLUZE™), leucemias agudas (Revuforj®) y tumores gástricos (Vyloy®).
BrightSpring Health Services (NASDAQ: BTSG)는 전문 약국 파트너인 Onco360®가 진행성 암과 혈액 질환 치료를 위한 여러 새로운 약물의 국가 약국 파트너로 선택되었음을 발표했습니다. 여덟 개의 새로운 약물이 Onco360의 유통 네트워크에 추가되었으며, 여기에는 유방암 (ITOVEBI™), 골수형성이상 증후군 (Rytelo™), 뇌 종양 (Voranigo®), 발작성 야간 헤모글로빈뇨 (PIASKY®), 식도 세포암 (Tevimbra®), 비소세포 폐암 (LAZCLUZE™), 급성 백혈병 (Revuforj®) 및 위 종양 (Vyloy®) 치료제가 포함됩니다.
BrightSpring Health Services (NASDAQ: BTSG) annonce que son partenaire en pharmacie spécialisée, Onco360®, a été sélectionné comme partenaire pharmaceutique national pour plusieurs nouveaux médicaments traitant des cancers avancés et des maladies du sang. Huit nouveaux médicaments ont été ajoutés au réseau de distribution d'Onco360, notamment des traitements pour : cancer du sein (ITOVEBI™), syndromes myélodysplasiques (Rytelo™), tumeurs cérébrales (Voranigo®), hémoglobinurie paroxystique nocturne (PIASKY®), carcinome à cellules œsophagiennes (Tevimbra®), cancer du poumon non à petites cellules (LAZCLUZE™), leucémies aiguës (Revuforj®) et tumeurs gastriques (Vyloy®).
BrightSpring Health Services (NASDAQ: BTSG) kündigt an, dass sein Partner für Spezialapotheken, Onco360®, als nationaler Apothekenpartner für mehrere neue Arzneimittel zur Behandlung von fortgeschrittenen Krebsarten und Blutkrankheiten ausgewählt wurde. Acht neue Arzneimittel wurden dem Verteilernetzwerk von Onco360 hinzugefügt, darunter Behandlungen für: Brustkrebs (ITOVEBI™), myelodysplastische Syndrom (Rytelo™), Gehirntumoren (Voranigo®), paroxysmale nächtliche Hämoglobinurie (PIASKY®), Ösophaguszellkarzinom (Tevimbra®), nicht-kleinzelliges Lungenkarzinom (LAZCLUZE™), akute Leukaämien (Revuforj®) und Magen Tumoren (Vyloy®).
- Expansion of Onco360's drug distribution network with 8 new specialty medications
- Enhanced market position in oncology and rare disease treatments
- Diversification of treatment portfolio across multiple cancer types and blood disorders
- None.
Insights
This partnership expansion significantly strengthens BrightSpring's specialty pharmacy business through Onco360. The selection as a distributor for eight new cancer and blood disorder treatments represents a major revenue opportunity in the high-margin specialty pharmacy sector. These medications target rare and difficult-to-treat conditions, typically commanding premium pricing.
Particularly notable are first-in-class therapies like Revuforj for rare leukemias and Vyloy for gastric cancer, which often carry higher reimbursement rates. The diverse portfolio spans breast cancer, brain tumors, lung cancer and blood disorders, providing revenue diversification. Specialty pharmacies typically generate
The drug portfolio represents breakthrough innovations in targeted therapy. Notably, Vyloy's CLDN18.2 targeting and Revuforj's menin inhibition showcase next-generation precision medicine approaches. The selection of these eight therapies positions Onco360 at the forefront of emerging oncology treatment paradigms, particularly in difficult-to-treat indications like IDH-mutated brain tumors and KMT2A-rearranged leukemias.
The breadth of coverage across multiple cancer types and rare blood disorders demonstrates Onco360's strong relationships with pharmaceutical manufacturers and validates their specialty pharmacy capabilities. This comprehensive access to novel therapies strengthens BrightSpring's competitive position in the oncology care delivery landscape.
LOUISVILLE, Ky., Nov. 26, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud of its specialty pharmacy partner, Onco360®, for being selected as the national pharmacy partner for multiple medications approved to treat advanced cancers and blood disease.
“Our partner Onco360 is rapidly bringing innovative medicines and treatments to market to help improve the lives of patients living with once untreatable, rare diseases,” said BrightSpring’s President and CEO, Jon Rosseau. “We are proud of their work to distribute breakthrough therapies and treatments to life-threatening diseases, expanding available care options, and extending the lives of many patients facing rare cancers and blood diseases.”
Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner for the following medications:
- ITOVEBI™ is approved to treat certain types of locally advanced or metastatic breast cancer.
- Rytelo™ is approved for the treatment of adult patients with myelodysplastic syndromes, a group of cancers that occur when the bone marrow produces immature blood cells.
- Voranigo® is approved for the treatment of adults and pediatric patients 12 years and older with certain types of brain tumors called astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation.
- PIASKY® is approved to treat adults and pediatric patients 13-years and older that have paroxysmal nocturnal hemoglobinuria, a life-threatening blood disorder that causes the destruction of red blood cells.
- Tevimbra® is approved for the treatment of adult patients with metastatic esophageal cell carcinoma after prior systemic chemotherapy.
- LAZCLUZE™ is approved as a first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.
- Revuforj® is the first and only menin inhibitor approved for the treatment of relapsed or refractory acute leukemias with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients.
- Vyloy® is currently the first and only approved monoclonal antibody specifically designed to target gastric tumor cells that express the biomarker claudin (CLDN) 18.2.
About BrightSpring Health Services:
BrightSpring Health Services provides complementary and integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily.
About Onco360 Oncology Pharmacy:
Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Specialty Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com.
Media Contact
Leigh White
Leigh.white@brightspringhealth.com
502.630.7412
FAQ
What new drugs has BrightSpring's Onco360 (BTSG) been selected to distribute in 2024?
What types of cancer does BrightSpring's (BTSG) Onco360 new drug portfolio treat?
Which blood disorders are treated by BrightSpring's (BTSG) Onco360 new medications?
